TRANSIENT MITOTIC PHASE LOCALIZATION OF BCL-2 ONCOPROTEIN IN HUMAN CARCINOMA-CELLS AND ITS POSSIBLE ROLE IN PREVENTION OF APOPTOSIS

被引:59
作者
WILLINGHAM, MC [1 ]
BHALLA, K [1 ]
机构
[1] MED UNIV S CAROLINA,DEPT MED,DIV HEMATOL ONCOL,CHARLESTON,SC 29425
关键词
BCL-2; MITOSIS; APOPTOSIS; PROGRAMMED CELL DEATH; IMMUNOCYTOCHEMISTRY; ONCOPROTEIN; TAXOL; CHEMOTHERAPY; ENDONUCLEASE; CHROMOSOMES;
D O I
10.1177/42.4.7907352
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We used a monoclonal antibody and fluorescence immunocytochemistry to localize the product of the bcl-2 gene in two cultured human carcinoma cell lines, KB and OVCAR-3. These cells show little or no localization of bcl-2 oncoprotein in interphase cells but demonstrate a dramatic appearance of bcl-2 in early prophase or late G(2), which persists throughout mitosis, rapidly disappearing at telophase. The pattern of bcl-2 localization shows a diffuse nuclear distribution before chromosome condensation, followed by a specific concentration of bcl-2 at the margins of condensed chromosomes in prophase, metaphase, and anaphase. Treatment of these cells with taxol, an agent that interferes with formation of the mitotic spindle, causes mitotic arrest and apoptosis after a prolonged incubation period. During mitotic arrest due to taxol, bcl-2 remains associated with condensed chromosomes but is lost after >2 days at approximately the same time as the appearance of apoptotic features in these cells. Western blotting indicates that the only extractable protein reactive with this monoclonal antibody under these conditions is a similar to 28 KD form of bcl-2. These results suggest a model for the role of bcl-2 in protection from apoptosis and a potentially common mechanism by which the final step of apoptosis might be mediated.
引用
收藏
页码:441 / 450
页数:10
相关论文
共 49 条
[1]  
ARRENDS MJ, 1990, AM J PATHOL, V136, P593
[2]   ACTIVATION OF PROGRAMMED CELL-DEATH (APOPTOSIS) BY CISPLATIN, OTHER ANTICANCER DRUGS, TOXINS AND HYPERTHERMIA [J].
BARRY, MA ;
BEHNKE, CA ;
EASTMAN, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) :2353-2362
[3]  
BHALLA K, 1993, LEUKEMIA, V7, P563
[4]   THE BCL-2 CANDIDATE PROTO-ONCOGENE PRODUCT IS A 24-KILODALTON INTEGRAL-MEMBRANE PROTEIN HIGHLY EXPRESSED IN LYMPHOID-CELL LINES AND LYMPHOMAS CARRYING THE T(14,18) TRANSLOCATION [J].
CHENLEVY, Z ;
NOURSE, J ;
CLEARY, ML .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (02) :701-710
[5]   CLONING AND STRUCTURAL-ANALYSIS OF CDNAS FOR BCL-2 AND A HYBRID BCL-2/IMMUNOGLOBULIN TRANSCRIPT RESULTING FROM THE T(14-18) TRANSLOCATION [J].
CLEARY, ML ;
SMITH, SD ;
SKLAR, J .
CELL, 1986, 47 (01) :19-28
[7]  
COHEN JJ, 1984, J IMMUNOL, V132, P38
[8]   A BIOCHEMICAL HALLMARK OF APOPTOSIS - INTERNUCLEOSOMAL DEGRADATION OF THE GENOME [J].
COMPTON, MM .
CANCER AND METASTASIS REVIEWS, 1992, 11 (02) :105-119
[9]   UNEXPECTED CYTOKINETIC EFFECTS INDUCED BY PUROMYCIN INCLUDE A G2-ARREST, A METAPHASE-MITOTIC-ARREST, AND APOPTOSIS [J].
DAVIDOFF, AN ;
MENDELOW, BV .
LEUKEMIA RESEARCH, 1992, 16 (11) :1077-1085
[10]  
DHEIN J, 1992, J IMMUNOL, V149, P3166